FXR as a novel therapeutic target for vascular disease

Drug News and Perspectives

Volumn 17, Issue 8, 2004, Pages 499-504

  Bishop Bailey, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; FARNESOID X RECEPTOR; LIGAND; LIPID; STEROID RECEPTOR; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CHOLESTEROL METABOLISM; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL TRACT; INFLAMMATORY CELL; LIPID METABOLISM; LIPID STORAGE; LIVER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANIMALS; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; GREAT BRITAIN; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; VASCULAR DISEASES;

EID: 10444281509     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2004.17.8.863693     Document Type: Review

References (52)

1. Forman, B.M., Goode, E., Chen, J. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-93.
2. Seol, W., Choi, H.S. and Moore, D.D. Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors. Mol Endocrinol 1995, 9: 72-85.
3. Zavacki, A.M., Lehmann, J.M., Seol, W., Willson, T.M., Kliewer, S.A. and Moore, D.D. Activation of the orphan receptor RIP14 by retinoids. Proc Natl Acad Sci USA 1997, 94: 7909-14.
4. Parks, D.J., Blanchard, S.G., Bledsoe, R.K. et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science 1999, 284: 1365-8.
5. Makishima, M., Okamoto, A.Y., Repa, J.J. et al. Identification of a nuclear receptor for bile acids. Science 1999, 284: 1362-5.
6. Bishop-Bailey D., Walsh, D.T. and Warner, T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 2004, 101: 3668-73.
7. Otte, K., Kranz, H., Kober, I. et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 2003, 23: 864-72.
8. Huber, R.M., Murphy, K., Miao, B. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290: 35-43.
9. Agellon, L.B. Metabolism and functions of bile acids. In: Biochemistry of Lipids, Lipoproteins and Membranes (4th Ed.). Vance and Vance (Eds.). Elsevier Science B.V., Amsterdam 2002, 433-48.
10. Carey, M.C. The enterohepatic circulation. In: The Liver: Biology and Pathobiology. I. Arias, H. Popper, D. Schachter and D.A. Shafritz (Eds.). Raven Press, New York 2001, 429-65.
11. Bahar, R.J. and Stolz, A. Bile acid transport. Gastroenterol Clin North Am 1999, 28: 27-58.
12. Redinger, R.N. The coming of age of our understanding of the enterohepatic circulation of bile salts. Am J Surg 2003, 185: 168-72.
13. Niesor, E.J., Flach, J., Lopes-Antoni, I., Perez, A. and Bentzen, C.L. The nuclear receptors FXR and LXRalpha: Potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des 2001, 7: 231-59.
14. Howard, W.R., Pospisil, J.A., Njolito, E. and Noonan, D.J. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol Appl Pharmacol 2000, 163: 195-202.
15. Chiang, J.Y.L. Bile acid regulation of gene expression: Roles of nuclear hormone receptors. Endocrine Rev 2002, 23: 443-63.
16. Willson, T.M., Jones, S.A., Moore, J.T. and Kliewer, S.A. Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev 2001, 21: 513-22.
17. Costantino, G., Macchiarulo, A., Entrena-Guadix, A., Camaioni, E. and Pellicciari, R. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). Bioorg Med Chem Lett 2003, 13: 1865-8.
18. Downes, M., Verdecia, M.A., Roecker, A.J. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003, 11: 1079-92.
19. Urizar, N.L., Liverman, A.B., Dodds, D.T. et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296: 1703-6.
20. Cui, J., Huang, L., Zhao, A. et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003, 278: 10214-20.
21. Glass, C.K. and Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000, 14: 121-41
22. Edwards, P.A., Kast, H.R. and Anisfeld, A.M. BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002, 43: 2-12.
23. Kassam, A., Miao, B., Young, P.R. and Mukherjee, R. Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J Biol Chem 2003, 278: 10028-32.
24. Ross, R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340: 115-26.
25. Gotto, A.M. Jr. Contemporary Diagnosis and Management of Lipid Disorders. 2nd Ed. Handbooks in Healthcare, Newtown, PA 1999.
26. Tu, H., Okamoto, A.Y. and Shan, B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc Med 2000, 10: 30-5.
27. Xu, G., Li, H., Pan, L.X. et al. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits. J Lipid Res 2003, 44: 1956-62.
28. Wang, H., Chen, J., Hollister, K., Sowers, L.C. and Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999, 3: 543-53.
29. Davis, R.A. and Hui, T.Y. 2000 George Lyman Duff Memorial Lecture: Atherosclerosis is a liver disease of the heart. Arterioscler Thromb Vasc Biol 2001, 21: 887-98.
30. Beil, U., Grouse, J.R., Einarsson, K. and Grundy, S.M. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982, 31: 438-44.
31. Auge, N., Rebai, O., Lepetit-Thevenin, J. et al. Pancreatic bile salt-dependent lipase induces smooth muscle cells proliferation. Circulation 2003, 108: 86-91.
32. Miyake, J.H., Wang, S.L. and Davis, R.A. Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase. J Biol Chem 2000, 275: 21805-8.
33. Debruyne, P.R., Bruyneel, E.A., Li, X., Zimber, A., Gespach, C. and Mareel, M.M. The role of bile acids in carcinogenesis. Mutat Res 2001, 480-481: 359-69.
34. Sinai, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G. and Gonzalez, F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 15: 731-44.
35. Lu, T.T., Makishima, M., Repa, J.J. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6: 507-15.
36. Goodwin, B., Jones, S.A., Price, R.R. et al. A regulatory cascade of the nuclear receptors FXR, SHP-I, and LRH-I represses bile acid biosynthesis. Mol Cell 2000, 6: 517-26.
37. Denson, L.A., Sturm, E., Echevarria, W. et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, NTCP. Gastroenterol 2001, 121: 140-7.
38. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D.J. and Suchy, F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001, 276: 28857-65.
39. Pircher, P.C., Kitto, J.L., Petrowski, M.L. et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem 2003, 278: 27703-11.
40. Grober, J., Zaghini, I., Fujii, H. et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 1999, 274: 29749-54.
41. Lambert, G., Amar, M.J., Guo, G., Brewer, H.B. Jr., Gonzalez, F.J. and Sinai, C.J. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003, 278: 2563-70.
42. Urizar, N.L., Dowhan, D.H. and Moore, D.D. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 2000, 275: 39313-7.
43. Anisfeld, A.M., Kast-Woelbern, H.R., Meyer, M.E. et al. Syndecan-1 expression is regulated in an isoform specific manner by the farnesoid-X receptor. J Biol Chem 2003, 278: 20420-8.
44. Mak, P.A., Kast-Woelbern, H.R., Anisfeld, A.M. and Edwards P.A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 2002, 43: 2037-41.
45. Kast, H.R., Nguyen, C.M., Sinai, C.J. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: A molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001, 15: 1720-8.
46. Prieur, X., Coste, H. and Rodriguez, J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003, 278: 25468-80.
47. Claudel, T., Inoue, Y., Barbier, O. et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003, 125: 544-55.
48. Claudel, T., Sturm, E., Duez, H. et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-1 transcription via a negative FXR response element. J Clin Invest 2002, 109: 961-71.
49. Pineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.C. and Staels, B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003, 17: 259-72.
50. Zhao, A., Lew, J.L., Huang, L. et al. Human kininogen gene is transactivated by the farnesoid X receptor. J Biol Chem 2003, 278: 28765-70.
51. Fruchart, J.C., Staels, B. and Duriez, P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res 2001, 44: 345-52.
52. Weinberger, C. A model for farnesoid feedback control in the mevalonate pathway. Trends Endocrinol Metab 1996, 7: 1-6.